Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background



Similar documents
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Malignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center

بسم هللا الرحمن الرحيم

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project

Sternotomy and removal of the tumor

Mesothelioma. Malignant Pleural Mesothelioma

MESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC

Recommendations for the Reporting of Pleural Mesothelioma

Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson

Ahmed Farouk Abd El-Hafez, MD

PET/CT in Lung Cancer

Protocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma

Malignant Mesothelioma

Malignant Mesothelioma

Understanding Pleural Mesothelioma

Clinical cases in Malignant Pleural Mesothelioma: Adherence to the ESMO Clinical Practice Guidelines

Update on Mesothelioma

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

Recommendations for cross-sectional imaging in cancer management, Second edition

Malignant pleural mesothelioma P/D vs. EPP

Small Cell Lung Cancer

Lung cancer LUNG CANCER. Box 1 Clinical signs

Primary -Benign - Malignant Secondary

Malignant Mesothelioma State of the Art

A Practical Guide to Advances in Staging and Treatment of NSCLC

SMALL CELL LUNG CANCER

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma

Choosing a Clinical Trial for Advanced Mesothelioma

Malignant Mesothelioma

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

Pleural and Chest Wall Tumors

Clinical Indications and Results Following Chest Wall Resection

Malignant Pleural Mesothelioma. NCCN Guidelines for Patients

Neoplasms of the LUNG and PLEURA

Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma

Screening, early referral and treatment for asbestos related cancer

Patterns of nodal spread in thoracic malignancies

FATAL PNEUMONITIS ASSOCIATED WITH INTENSITY-MODULATED RADIATION THERAPY FOR MESOTHELIOMA

Malignant Pleural Mesothelioma in Singapore

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms

Probe: Could you tell me about when?

Case Report A Cause of Bilateral Chylothorax: A Case of Mesothelioma without Pleural Involvement during Initial Diagnosis

Current Status and Perspectives of Radiation Therapy for Breast Cancer

Lung Cancer Treatment Guidelines

Lung cancer forms in tissues of the lung, usually in the cells lining air passages.

Calculation of Contra-lateral Lung Doses in Thoracic IMRT: An Experimental Evaluation

General Rules SEER Summary Stage Objectives. What is Staging? 5/8/2014

Mesothelioma: Questions and Answers

Summary of treatment benefits

III. EXTENT OF DISEASE

Treatment of Malignant Pleural Mesothelioma: Is There a Benefit to Pleuropneumonectomy?

Treating Mesothelioma - A Quick Guide

What is Mesothelioma?

B. Dingle MD, FRCPC, Brian Yaremko MD,FRCPC, R. Ash, MD, FRCPC, P. Truong, MD, FRCPC

Diseases. Inflammations Non-inflammatory pleural effusions Pneumothorax Tumours

Cardiac Masses and Tumors

understanding mesothelioma

Brigham and Women s Hospital, Boston, MA, USA; 2 Verastem, Inc., Boston, MA, USA

Surgical therapy of. who should be operated

Malignant pleural mesothelioma: outcome of limited surgical management

How To Understand How Cancer Works

Therapy of pleural effusions Modern techniques

How To Treat Malignant Pleural Mesothelioma

Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases

How To Write Lung Cancer Data Standards For Nhs Scotland

POLICY A. INDICATIONS

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology

Innovative RT SBRT. The variables with REQ in superscript are required.

How To Know When To Stage Lung Cancer

Stage I, II Non Small Cell Lung Cancer

British Thoracic Society Standards of Care Committee

Surgical treatment for malignant pleural mesothelioma: extrapleural pneumonectomy, pleurectomy/decortication or extended pleurectomy?

Thoracic 18F-FDG PETCT

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md

Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

Contemporary Management of Malignant Pleural Mesothelioma

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians

INFLAMMATORY PLEURAL EFFUSION

The Need for Accurate Lung Cancer Staging

CT findings in Differential Diagnosis between Tuberculous Pleurisy and Malignant Effusion

Mesothelioma , The Patient Education Institute, Inc. ocft0101 Last reviewed: 03/21/2013 1

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3

Transcription:

Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the pleura with an emphasis on mesothelioma To describe the role of PET/CT in the staging of mesothelioma and factors that determine resectability To review recent trends in treatment of mesothelioma Benign meso, localized meso, solitary fibrous meso, LFTOP M = F, 20-70 y.o. 50 % asymptomatic, but HPO and hypoglycemia 80% arise from visceral pleura Often pedunculated, surgery, 10% recurrence Rosado-de-Christenson; Radiographics, 23(3):759-83, 2003 Sensitivity Specificity Circumferential Distribution 100% 41% Pleura >1cm Thickness 94% 36% Nodular Morphology 94% 51% Pleural fluid or pleural implants Involves visceral and parietal pleura Cytology positive: 40-80 % Primary: lung most common, lymphoma, breast, pancreas, stomach, ovary, melanoma Background 88

Tumor Histology Staging Evaluation of MPM The primary imaging modality used in the diagnosis, staging, and treatment management of malignant pleural mesothelioma is CT. CT can assess for involvement of the chest wall, diaphragm, lungs, and mediastinum. Contrast enhanced CT shows circumferential nodular right pleural thickening and right hilar (arrow) and subcarinal adenopathy (asterisk). SUNDAY * Staging Evaluation of MPM CT is readily available and most frequently used in evaluating patients for surgical resection, and findings that preclude surgery include metastatic disease to the: Staging: MRI vs. CT MRI is superior to CT in accuracy of evaluation for invasion of endothoracic fascia or a single chest wall focus of involvement (MRI 69% vs. CT 46%). Note the obliteration of the endothoracic fascia and extrapleural fat plane (arrow) adjacent to the right pleural mass. Staging: MRI vs. CT vs. Laparoscopy Although MRI is superior to CT in accuracy for evaluation of diaphragmatic invasion (MRI 82% vs. CT 55%), extended surgical staging with direct visualization of the undersurface of the diaphragm with laparoscopy and peritoneal lavage can detect small volume disease missed on MRI. Staging: PET/CT PET/CT allows precise anatomic localization of areas of increased FDG uptake and can be useful in guiding biopsy of these sites. FDG avid foci in the bilateral supraclavicular regions (arrows) are suspicious for N3 disease and prompted node biopsy. 89

Staging: PET/CT The strength of PET/CT in staging is the detection of extrathoracic metastases. PET/CT identified occult metastases in 25% of patients being evaluated for surgery in one study. In more than half of these patients, extrathoracic metastases were not identified by routine clinical and conventional radiologic evaluation. PET/CT shows left MPM with solitary metastasis to right proximal humerus (arrow). No lytic or blastic lesion seen on CT. Staging and Resectability T2 Tumor involving each ipsilateral pleural surface with at least one of the following features: involvement of diaphragmatic muscle confluent visceral pleural tumor (including fissures) extension of tumor from visceral pleura into underlying pulmonary parenchyma 90

Chemotherapy Standard of care for first-line systemic therapy for MPM is cisplatin and pemetrexed, a multitargeted antifolate. In a multicenter phase III study of 448 patients, this combination had an objective response rate of 41% and improved overall survival by 3 months. CT shows response to therapy of right nodular pleural thickening (arrow). Surgery Extrapleural pneumonectomy (EPP) is the radical en bloc resection of the lung, pleura, diaphragm, and pericardium. Fusion of the pleura at the central tendon of the diaphragm and the lateral portion of the pericardium mandates resection and subsequent reconstruction with a prosthetic patch. Pleurectomy and decortication (P/D) is a lung-sparing operation in which the diseased pleural envelope that encases and constricts the lung is mobilized off the chest wall, mediastinum, diaphragm and pericardium, and then stripped from the surface of the lung. SUNDAY Ongoing debate in terms of which is the preferred surgical approach. Although EPP is associated with a higher morbidity (25%) and surgical mortality (4 15%), it provides more complete tumor cytoreduction than P/D, and the empty thorax permits the use of high-dose radiotherapy postoperatively. In contrast, P/D is associated with lower morbidity and mortality (1 5%), but complete tumor cytoreduction is less frequently attainable. Surgery Intensity Modulated Radiation Therapy (IMRT) Following Surgery for Local Control Sarcomatoid histology and the presence of positive extrapleural nodes usually preclude surgery. Favorable outcome is characterized by minimal or limited local regional disease, disease-free incomplete fissures, and epithelial histology. The region of the removed pleura is contoured by the radiation oncologist in consultation with the surgeon to carefully delineate appropriate target volumes to include all involved pleural surfaces, ipsilateral mediastinal lymph nodes, the retrocrural space, and the deep margin of the thoracotomy incision. Multiple beams and inverse planning are used to treat the region at risk to the same dose of 45 Gy in 25 fractions while placing dose constraints on normal structures such as the heart, kidney, spinal cord, and stomach. Negative prognostic factors for survival include involvement of lymph nodes outside the pleural envelope and tumor detected at the parietal, mediastinal, diaphragmatic, and pericardial resection margins. Conventional anatomic imaging is an integral component in the evaluation and management of patients with benign and malignant pleural diseases. Conclusion PET/CT and surgical staging procedures are useful in improving the accuracy of clinical staging of malignant pleural mesothelioma. 91

References 92